A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
Critical

Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I

Detected July 16, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

DEA places MDMB-4en-PINACA into Schedule I, making it illegal to manufacture, distribute, or possess without a DEA registration. This affects any business handling this synthetic cannabinoid.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Critical. All pharmaceutical manufacturers, API suppliers, and compounders handling MDMB-4en-PINACA or related substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective immediately upon publication (April 24, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

MDMB-4en-PINACA is now a Schedule I controlled substance with no accepted medical use and high abuse potential.

Who it affects

All pharmaceutical manufacturers, API suppliers, and compounders handling MDMB-4en-PINACA or related substances.

What you must do

Immediately cease all manufacturing, distribution, and possession of MDMB-4en-PINACA unless you have a DEA Schedule I research registration.

Deadline

Effective immediately upon publication (April 24, 2026).

Source: https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)